Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
Provided By GlobeNewswire
Last update: Jun 2, 2025
CORAL GABLES, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of William (Will) T. Andrews, MD, FACP as Chief Medical Officer. Dr. Andrews will report directly to the Company’s President and Chief Executive Officer, Richard J. Daly, and will serve as a member of the Company’s executive leadership team. He succeeds Dr. Gary Ingenito, who is retiring after a successful career and will support the transition in a consulting capacity.
Read more at globenewswire.comNASDAQ:CPRX (6/12/2025, 3:11:10 PM)
24.33
-1.08 (-4.25%)
Find more stocks in the Stock Screener
CPRX Latest News and Analysis
5 days ago - ChartmillCATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Rare Combination of Growth and ValueCATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and an attractive valuation, making it a standout in biotech.
8 days ago - ChartmillCATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for CANSLIM InvestorsCATALYST PHARMACEUTICALS (CPRX) meets CANSLIM criteria with strong earnings growth, high relative strength, and solid fundamentals. A technical uptrend and reasonable valuation add to its appeal.
10 days ago - ChartmillCATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for Growth InvestorsCATALYST PHARMACEUTICALS INC (CPRX) meets key growth criteria from Louis Navellier’s strategy, with strong earnings, revenue growth, and solid financial health. A detailed analysis highlights its potential for investors.
19 days ago - ChartmillCATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for Quality InvestorsCatalyst Pharmaceuticals (CPRX) shows strong fundamentals, high profitability, and zero debt, making it a compelling choice for quality investors. The stock trades at reasonable valuations with solid growth prospects.
